The epilepsy therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019 according to new research report
Print
01 June 2015
WhaTech
The Epilepsy Therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019.
Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma.
About Epilepsy Therapeutics
However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures.
An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.
This report covers the present scenario and the growth prospects of the Epilepsy Therapeutics market in the APAC for the period 2015-2019.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market in the region. In addition, it discusses the major drivers that influence the growth of the market.
It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Epilepsy Therapeutics Market in the APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the APAC regions; it also covers the market landscape and its growth prospects in the coming years.
The report also includes a discussion of the key vendors operating in this market.
Our analyst researched the following companies as the key players in the Epilepsy Therapeutics Market in the APAC Region: Eisai Inc., GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Other Prominent Vendors in the market are: Abbvie, Acorda Therapeutics, Dainippon Sumitomo Pharma, Janssen Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Meda, Novartis, Roche, Sage Therapeutics, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith Laboratories and Valeant Pharmaceuticals.
Commenting on the report, an our analyst said: “The reformulation of marketed drugs is one key trend emerging in the market. Reformulated drugs usually have better tolerability and better dosage regimens than the original drugs and this increases the acceptance of such drugs and increases the revenue generated through their sales.”
According to the report, high unmet medical needs in terms of availability of safe, efficacious, and epilepsy-modifying treatments are one of the major drivers of the market. Any drug that can overcome these deficits is expected to drive the market during the forecast period.
Further, the report states that generic erosion is one of the major challenges faced by the market in the APAC region as this decreases the revenue of individual branded drugs in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.